Inhibition of the androgen receptor by antisense oligonucleotides regulates the biological activity of androgens in SZ95 sebocytes

Hormone and Metabolic Research

Volumn 39, Issue 2, 2007, Pages 149-156

  Fimmel, S ^b   Saborowski, A ^b   Terouanne B ^c   Sultan, C ^c   Zouboulis, C C ^a,b  

^a DESSAU MEDICAL CENTER   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSERM   (France)

Author keywords

Androgens; Biological activity; Sebaceous glands; Transient transfection

Indexed keywords

2' O METHYLRIBONUCLEOTIDE DERIVATIVE; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; METRIBOLONE; PHOSPHOROTHIOIC ACID DERIVATIVE; RIBONUCLEOTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BIOLOGICAL ACTIVITY; CELL DEATH; CELL PROLIFERATION; CELL SIZE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CELL; SKIN FIBROBLAST;

ANDROGENS; CELL DEATH; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; METRIBOLONE; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, ANDROGEN; SEBACEOUS GLANDS; SKIN; TRANSFECTION;

EID: 34047209460     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-961815     Document Type: Article

References (54)

1. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD: Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003; 278: 5052-5061
2. Verrijdt G, Haelens A, Claessens F: Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 2003; 78: 175-185
3. Zouboulis CC: Human skin: an independent peripheral endocrine organ. Horm Res 2000; 54: 230-242
4. Hirawat S, Budman DR, Kreis W: The androgen receptor: structure, mutations, and antiandrogens. Cancer Invest 2003; 21: 400-417
5. Lee DK, Chang C: Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 2003; 88: 4043-4054
6. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A: Androgen receptors in prostate cancer. J Urol 2003; 170: 1363-1369
7. Khalkhali-Ellis Z, Handa RJ, Price RH, Jr, Adams BD, Callaghan JJ, Hendrix MJ: Androgen receptors in human synoviocytes and androgen regulation of interleukin 1beta (IL-1beta) induced IL-6 production: a link between hypoandrogenicity and rheumatoid arthritis? J Rheumatol 2002; 29: 1843-1846
8. Ibanez L, Ong KK, Mongan N, Jaaskelainen J, Marcos MV, Hughes IA, De Zegher F, Dunger DB: Androgen receptor gene CAG repeats polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003; 88: 3333-3338
9. Sasaki M, Sakuragi N, Dahiya R: The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients. Biochem Biophys Res Commun 2003; 305: 1105-1108
10. Chen W, Thiboutot D, Zouboulis ChC: Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 2002; 119: 992-1007
11. Elias P, Feingold K: Coordinate regulation of epidermal differentiation and barrier homeostasis. Skin Pharmacol Appl Skin Physiol 2001; 14: 28-34
12. Kao JS, Garg A, Mao-Qiang M, Crumrine D, Ghadially R, Feingold KR, Elias PM: Testosterone perturbs epidermal permeability barrier homeostasis. J Invest Dermatol 2001; 116: 443-451
13. Ashcroft G, Mills S: Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest 2002; 110: 615-624
14. Zouboulis ChC, Degitz K: Androgen action on human skin - from basic research to clinical significance. Exp Dermatol 2004; 4: 5-10
15. Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, De La Taille A, Ackermann R, Burchardt M: The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signalling. Int J Oncol 2003; 23: 10095-10102
16. Hoffmann J, Sommer A: Steroid hormone receptors as targets for the therapy of breast and prostate cancer - recent advances, mechanisms of resistance and new approaches. J Steroid Biochem Mol Biol 2005; 93: 191-200
17. Chi KN, Gleave ME: Antisense approaches in prostate cancer. Expert Opin Biol Ther 2004; 6: 927-936
18. Hamy F, Brondani V, Spoerri R, Rigo S, Stamm C, Klimkait T: Specific block of androgen receptor activity by antisense oligonucleotides. Prostate Cancer Prostatic Disc 2003; 6: 27-33
19. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE: Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005; 96: 251-258
20. Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP: Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol 2004; 172: 1140-1144
21. Fimmel S, Kurfurst R, Bonté F, Zouboulis CC: Responsiveness to androgens and effectiveness of antisense oligonucleotides against the androgen receptor on human epidermal keratinocytes is dependent on the age of the donor and the location of cell origin. Horm Metab Res 2007; 39: 157-165
22. Zouboulis ChC, Seltmann H, Neitzel H, Orfanos CE: Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 1999; 113: 1011-1020
23. Boudon C, Lobaccaro JM, Lumbroso S, Ogur G, Ocal G, Belon C, Sultan C: A new deletion of the 5alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency. Clin Endocrinol 1995; 43: 183-188
24. Fimmel S, Saborowski A, Orfanos CE, Zouboulis ChC: Development of efficient transient transfection systems for introducing antisense oligonucleotides into human epithelial skin cells. Horm Res 2000; 54: 306-311
25. Oshima A, Kyle JW, Miller RD, Hoffmann JW, Powell PP, Grubb JH, Sly WS, Tropak M, Guise KS, Gravel RA: Cloning, sequencing, and expression of cDNA for human beta- glucuronidase. Proc Natl Acad Sci USA 1987; 84: 685-689
26. Wróbel A, Seltmann H, Fimmel S, Müller-Decker K, Tsukada M, Bogdanoff B, Mandt N, Blume-Peytavi U, Orfanos CE, Zouboulis ChC: Differentiation and apoptosis in human immortalized sebocytes. J Invest Dermatol 2003; 120: 175-181
27. Gillies RJ, Didier N, Denton M: Determination of cell number in monolayer cultures. Anal Biochem 1986; 159: 109-113
28. Nirde P, Georget V, Terouanne B, Galifer RB, Belon C, Sultan C: Quantitation of androgen receptor messenger RNA from genital skin fibroblasts by reverse transcription-competitive polymerase chain reaction. J Steroid Biochem Mol Biol 1998; 66: 35-43
29. Kemppainen JA, Lane MV, Sar M, Wilson EM: Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 1992; 267: 968-974
30. Kimura K, Markowski M, Bowen C, Gelmann EP: Androgen blocks apoptosis of hormone- dependent prostate cancer cells. Cancer Res 2001; 61: 5611-5618
31. Gad YZ, Berkovitz GD, Migeon CJ, Brown TR: Studies of up-regulation of androgen receptors in genital skin fibroblasts. Mol Cell Endocrinol 1988; 57: 205-213
32. Chen W, Yang CC, Sheu HM, Seltmann H, Zouboulis ChC: Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 2003; 121: 441-447
33. Marcusson EG, Bhat B, Manoharan M, Bennett CF, Dean NM: Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acid Res 1998; 26: 2016-2023
34. Wang L, Prakash RK, Stein CA, Koehn RK, Ruffne DE: Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev 2003; 13: 169-189
35. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D: Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism in vivo. Proc Natl Acad Sci USA 1996; 93: 15481-15484
36. Agrawal S, Temsamani J, Galbraith W, Tang J: Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 1995; 28: 7-16
37. Crooke ST, Lemonidis KM, Neilson L, Griffey R, Lesnik EA, Monia BP: Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide- RNA duplexes. Biochem J 1995; 312: 599-608
38. Kurreck J, Wyszko E, Gillen C, Erdmann VA: Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 2002; 30: 1911-1918
39. Baker BF, Lot SS, Condon TP, Cheng S, Flournoy F, Lesnik EA, Sasmor H, Bennett CF: 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997; 272: 1994-2000
40. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA: Pharmacokinetic properties of 2′-O-(2-methoxy-ethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001; 296: 890-897
41. Schmitz JC, Yu D, Agrawal S, Chu E: Effect of 2′-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells. Nucleic Acids Res 2001; 29: 415-422
42. Spiller DG, Giles RV, Broughton CM, Grzybowski J, Ruddell CJ, Tidd DM, Clark RE: The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog- mediated biologic responses. Antisense Nucleic Acid Drug Dev 1998; 8: 281-293
43. Ranganathan G, Song W, Dean N, Monia B, Barger SW, Kern PA: Regulation of lipoprotein lipase by protein kinase C alpha in 3T3-F442A adipocytes. J Biol Chem 2002; 277: 38669-38675
44. Reid J, Betney R, Watt K, McEwan IJ: The androgen receptor transactivation domain: the interplay between protein conformation and protein-protein interactions. Biochem Soc Trans 2003; 31: 1042-1046
45. Grino PB, Griffin JE, Wilson JD: Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 1990; 126: 1165-1172
46. Fritsch M, Orfanos CE, Zouboulis ChC: Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001; 116: 793-800
47. Rosenfield RL, Deplewski D, Kentsis A, Ciletti N: Mechanism of androgen induction of sebocyte differentiation. Dermatology 1998; 196: 43-46
48. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD: Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995; 52: 459-467
49. Song CS, Jung MH, Supakar PC, Chen S, Vellanoweth RL, Chatterjee B, Roy AK: Regulation of androgen action by receptor gene inhibition. Ann NY Acad Sci 1995; 761: 97-108
50. Yeap BB, Krueger RG, Leedman PJ: Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 1999; 40: 3282-3291
51. Krongrad A, Wilson CM, Wilson JD, Allman DR, McPhaul MJ: Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 1991; 76: 79-88
52. Wolf DA, Herzinger T, Hermeking H, Blaschke D, Horz W: Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol Endocrinol 1993; 7: 924-936
53. van Erp PE, Wingens M: Does antisense make sense in Dermatology? Acta Derm Venereol 2001; 81: 385-391
54. Verma DD, Verma S, Blume G, Fahr A: Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study. Eur J Pharm Biopharm 2003; 55: 271-277